Clinical Trial Update: A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SRT501 alone or with bortezomib in multiple myeloma was terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• SRT501

Snippet

Sponsor: Sirtris, a GSK Company | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2019-02-27